Navigation Links
Study of Drug Therapy for Compulsive Buying Yields a Puzzle,,Stanford Researcher Says

STANFORD, Calif.--(BUSINESS WIRE)--Mar 14, 2007 - Researchers at the Stanford University School of Medicine say they are puzzled by findings from their new study indicating that an antidepressant, which previously showed promise in treating a behavioral disorder known as compulsive buying, did not result in a sustained benefit for the patients who took it.

The medication is escitalopram, a commonly prescribed antidepressant sold under the brand name Lexapro. In the study, researchers found no difference in the relapse rate of people with compulsive-buying disorder when they continued to take escitalopram compared with those who had been switched to a placebo. Those results are perplexing to lead author Lorrin Koran, MD, professor of psychiatry and behavioral sciences emeritus, because he had done a similar study in 2003 that found compulsive-buying patients improved stably after taking another antidepressant medication, citalopram, in which escitalopram is the active ingredient.

"It was a shock that, when we did the trial again with the active ingredient, it didn't work exactly the same way. It should have," said Koran, who also led the 2003 study. The results of the latest double-blind, placebo-controlled trial will be published in the April issue of the Journal of Clinical Psychopharmacology.

Koran said the unexpected result from the new study may in part be due to the small number of participants in the double-blind phase of the trial, which involved just 17 subjects whose buying behavior had markedly improved in the initial stage of the trial when they were all taking escitalopram. Of the nine randomly assigned to take a placebo in the later part of the trial, six relapsed, while five of eight continuing on escitalopram relapsed.

But the study size is likely not the only factor influencing the outcome of the trial.

"I don't think we're dealing with one pure biological disorder,"
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/2/2015)... OAKS, Calif. , Sept. 2, 2015 /PRNewswire/ ... the submission of a Marketing Authorization Application (MAA) ... centralized procedure for etelcalcetide (formerly AMG 416) for ... patients with chronic kidney disease (CKD) on hemodialysis ... calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Element(TM) Stent now available in select markets worldwideNATICK, ... BSX ) today announced the launch ... Stent System in select markets worldwide. The ... alloy engineered specifically for coronary stent applications and ...
... May 18 Shire plc (LSE: SHP, ... company, today announced new findings on INTUNIV (guanfacine) extended ... This randomized placebo controlled trial met its primary objective, ... oppositional symptoms in children aged 6 to 12 years ...
Cached Medicine Technology:Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 2Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 3Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 4Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms 5
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, ... announced the two leaders who will deliver keynote presentations at the upcoming Digital ... Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury ... truly superb luxury vehicles based on which of the latest and greatest vehicles their ... step forward in pursuit of this goal: a 2015 Rolls Royce Wraith rental ...
(Date:9/2/2015)... ... September 02, 2015 , ... The Western ... and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred Goldstein Endowment ... months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, MD, PhD ...
(Date:9/2/2015)... ... 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to 4 ... Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The ... best-selling author Sam Keen based on his new book which he co-authored with his ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... safety and efficacy endpoint data collection, cloud analytics and workflow solutions today ... The series enables pharmaceutical researchers to participate in interactive programs in which ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... Dec. 2 TROY Group, Inc.,(Pink Sheets: TROY), ... the first digital printer for printing the federally,mandated ... TROY SecureRx,printer allows healthcare providers to significantly reduce ... security regulations,established by the Center for Medicare and ...
... SAN JOSE, Calif., Dec. 2 eOn Communications,Corporation(TM) (Nasdaq: ... announced today that it has received a contract from ... at the Landstuhl Regional Medical,Center in Germany. Implementation ... April of 2009. , ...
... Shower(TM) brand just got,better with the addition of its new ... flavor contains Lifeguard(TM) Protection, a fortification,package with powerful antioxidant vitamins ... leading brands. , "We ... Sun Shower(TM) Super,Blends iced coffees, teas and lattes," said Chris ...
... SACRAMENTO, Calif., Dec. 2 MRME the publisher of ... the American,College of Cardiology (CA ACC), the largest ACC ... and impactful educational programs for,cardiologists. The CA ACC is ... of medical education activities. , ...
... and improves attention to the scan, study shows , , TUESDAY, ... the patient next to their radiological scans helps humanize each ... by radiologists, a new study finds. , As technological ... patient, putting a patient,s photo in his or her file ...
... MANCHESTER, N.H., Dec. 2 Anthem Blue Cross and ... have pledged more than,$175,000 to support over 220 not-for-profit ... Giving Campaign. The Anthem Blue Cross and Blue,Shield Foundation ... the total to more than $260,000 , ...
Cached Medicine News:Health News:TROY SecureRx Revolutionizes Prescription Printing 2Health News:TROY SecureRx Revolutionizes Prescription Printing 3Health News:TROY SecureRx Revolutionizes Prescription Printing 4Health News:eOn Communications Announces GSA Contract 2Health News:eOn Communications Announces GSA Contract 3Health News:New Sun Shower(TM) Super Blends: Iced Coffees, Teas, Lattes With Half the Calories 2Health News:Patients' Photos Help Boost Radiologists' Accuracy 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations 3
Trial lens set +/- Cyl....
...
... of engineering and innovative design, the Burton ... and masterful workmanship. At Burton, we set ... industry a truly innovative concept, but to ... to quality construction and stringent testing, we ...
... Durable cast iron and steel construction for ... quiet and reliable up/down chair movement. Soft, ... of lasting comfort. Electro-magnetic counter-balanced slit lamp ... Low, only 24" high slit lamp arm ...
Medicine Products: